Cadre Holdings, Inc. SEC filings document the company's safety-equipment business, public-company governance and NYSE-listed common stock. Form 8-K reports cover operating results, financial condition, Regulation FD presentations, material events and related exhibits for its law enforcement, first responder, military and nuclear safety markets.
Cadre's filings also include proxy materials for annual meeting matters, board and stockholder voting procedures, and corporate governance disclosures. Financial-result filings discuss GAAP measures alongside non-GAAP metrics such as EBITDA, adjusted EBITDA and adjusted EBITDA margin, while event reports address material agreements, acquisition-related communications, capital-structure disclosures and security registration details for CDRE common stock.
Cadre Holdings, Inc. reported strong top-line growth for the three and six months ended June 30, 2026. Net sales rose to $207.1 million for the quarter, up 31.8% from $157.1 million, and to $362.6 million year-to-date, up 26.2%. Gross profit reached $87.1 million for the quarter. Operating income increased to $22.5 million, while quarterly net income edged down to $11.4 million from $12.2 million as higher contingent consideration, compensation, interest expense and adverse foreign currency effects offset margin gains. Adjusted EBITDA grew to $42.0 million in the quarter and $63.1 million year-to-date.
The company accelerated its acquisition strategy, closing the $185.2 million TYR Tactical deal and the $10.3 million Alien Gear holsters acquisition, expanding the Product segment and increasing goodwill and intangibles to $408.1 million. Total assets rose to $917.3 million, funded partly by higher term debt of $375.9 million, while cash, cash equivalents and restricted cash declined to $57.7 million. Orders backlog nearly doubled to $367.7 million, supported by large orders for blast attenuation seats, sensors, remotely operated vehicles, nuclear safety products and duty gear holsters, providing visibility into future revenue.
Cadre Holdings reported strong Q2 2026 results, with net sales of $207.1 million up from $157.1 million a year earlier and gross profit rising to $87.1 million. Adjusted EBITDA increased to $42.0 million with a 20.3% margin versus 17.2%, while net income was $11.4 million compared with $12.2 million. For the first half of 2026, net sales reached $362.6 million versus $287.2 million and adjusted EBITDA was $63.1 million, but net income declined to $13.4 million from $21.5 million.
Orders backlog reached a record $368 million, supporting an increased 2026 outlook for net sales of $749–$769 million and adjusted EBITDA of $139–$144 million, with expected capital expenditures of $10–$14 million. The company completed the acquisition of Alien Gear Holsters, highlighted Safariland’s role in a five‑year, $61.0 million FBI IDIQ armor program, and declared a quarterly cash dividend of $0.10 per share. Cash, cash equivalents and restricted cash totaled $57,669 thousand at June 30, 2026.
Cadre Holdings, Inc. amended and restated its Canadian revolving credit facility, allowing its Canadian subsidiaries Med-Eng Holdings ULC, Pacific Safety Products Inc., ICOR Technology Inc. and TYR Tactical Canada ULC to borrow up to CDN$20.0 million, including up to CDN$6.0 million for letters of credit. The Revolving Canadian Loan matures on December 20, 2029 and is guaranteed by Safariland, LLC.
Borrowings may be in U.S. or Canadian dollars and bear interest at base rate, SOFR, Canadian Prime Rate or CORRA benchmarks plus margins ranging from 0.50% to 2.50% per annum, depending on Cadre’s consolidated total net leverage ratio. An unused line fee of 0.175% to 0.25% per annum applies, and the agreement includes customary covenants and events of default.
Cadre Holdings, Inc. insider Warren B. Kanders, through affiliated entity Kanders SAF, LLC, reported open-market sales of a total of 75,000 shares of Common Stock. On June 18, Kanders SAF, LLC sold 25,000 shares at a weighted average price of $27.86 per share, in multiple trades within a $27.49–$28.42 range. On June 22, it sold an additional 50,000 shares at a weighted average price of $27.43 per share, with individual trades between $27.28–$27.67. Following these transactions, Kanders SAF, LLC held 9,667,039 shares after the June 18 sale and 9,617,039 shares after the June 22 sale, indicating the sales were a small portion of the reported indirect position. Separate holding entries show 1,305,650 shares held by a Warren B. Kanders Roth IRA, 23,450 shares held by an Allison Kanders Roth IRA, and 22,888 shares held directly, all as of June 18. Footnotes state Kanders is the sole manager and member of Kanders SAF, LLC and that he disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest.
Cadre Holdings, Inc. director Mary E. Kissel received a grant of stock options for 17,393 shares of common stock. The options have an exercise price of $28.75 per share and expire on June 16, 2036, functioning as equity-based compensation rather than an open-market purchase.
These options were granted under the company’s 2021 Stock Incentive Plan. They vest in four installments: 4,349 shares on June 30, 2026, and 4,348 shares on each of September 30, 2026, December 31, 2026, and March 31, 2027. All holdings reported are direct.
Cadre Holdings director William G. Quigley III received a grant of stock options for 17,393 shares of common stock at an exercise price of $28.75 per share. The options were granted under Cadre’s 2021 Stock Incentive Plan as equity-based compensation.
These options vest in four installments: options to purchase 4,349 shares vest and become exercisable on June 30, 2026, and options to purchase 4,348 shares vest and become exercisable on each of September 30, 2026, December 31, 2026, and March 31, 2027. Any unexercised options expire on June 16, 2036.
Cadre Holdings, Inc. large shareholder Warren B. Kanders filed an amended Schedule 13D reporting beneficial ownership of 11,392,928 common shares, or about 26.4% of the company. This total includes 9,692,039 shares held by Kanders SAF, options for 348,901 shares that are currently exercisable within 60 days, and 1,329,100 shares held through Roth IRAs for Mr. and Mrs. Kanders.
The filing notes that 3,750,000 of the beneficially owned shares are subject to a security interest in favor of Texas Capital Bank under a loan agreement. Kanders SAF separately reports beneficial ownership of 9,692,039 shares, representing about 22.6% of the outstanding common stock.
The amendment also discloses recent open-market sales by Kanders SAF: 100,000 shares on June 15, 2026 at a weighted average price of $30.03 per share, 100,000 shares on June 16, 2026 at $28.19 per share, and 25,000 shares on June 17, 2026 at $28.68 per share.
Cadre Holdings, Inc. reported that director Hamish Norton received a grant of stock options to purchase 17,393 shares of common stock at an exercise price of $28.75 per share under the company’s 2021 Stock Incentive Plan. The options expire on June 16, 2036 and vest in four installments between June 30, 2026 and March 31, 2027.
Cadre Holdings director Nicolas Sokolow received a grant of stock options to buy 17,393 shares of common stock at an exercise price of $28.75 per share. These options expire on June 16, 2036 and were issued under the company’s 2021 Stock Incentive Plan.
According to the vesting schedule, options for 4,349 shares will vest and become exercisable on June 30, 2026. Additional tranches of 4,348 options will vest and become exercisable on each of September 30, 2026, December 31, 2026, and March 31, 2027.
Cadre Holdings, Inc. reported new equity awards for its Chief Financial Officer, Blaine Browers. He received stock options for 115,000 and 92,500 shares of common stock at an exercise price of $28.75 per share, along with restricted stock unit awards covering 69,500 and 48,500 shares.
All four grants are performance-based. The RSUs vest only if the common stock reaches a volume-weighted average price of at least $60.00 or $80.00 per share, depending on the tranche, over a 20 consecutive trading day period on or before June 16, 2033, and then only after the third anniversary of grant. The options have similar VWAP hurdles of $60.00 and $80.00 per share and become exercisable on the later of meeting those conditions and the third anniversary.